User login
Key clinical point: Among human leukocyte antigen (HLA)-matched donor-recipient pairs (DRPs) who underwent unrelated donor hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), higher inhibitory and missing killer immunoglobulin-like receptors (KIRs) were associated with a reduced risk for relapse, but without any survival advantage.
Major finding: Higher inhibitory KIR (subhazard ratio [SHR], 0.86; P = .01) and missing KIR (SHR, 0.84; P = .02) scores were associated with a reduced risk for relapse. Patients with inhibitory ‘maxima’ (IM)-KIR of 5 had a lower risk for relapse (SHR, 0.80; P = .004) vs those with IM of less than 5. However, increased transplant-related mortality (SHR, 1.32; P less than .05) was observed in 8/8 HLA-matched DRPs with IM 5 vs less than 5.
Study details: Findings are from a retrospective analysis of 2,365 DRPs who underwent unrelated donor HCT with HLA match grade of 8/8 (85%) or 7/8 for early- or intermediate-risk AML.
Disclosures: No specific source of funding was identified for this work. The authors declared no conflicts of interest.
Source: Krieger E et al. Bone Marrow Transplant. 2021 Jul 7. doi: 10.1038/s41409-021-01393-9.
Key clinical point: Among human leukocyte antigen (HLA)-matched donor-recipient pairs (DRPs) who underwent unrelated donor hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), higher inhibitory and missing killer immunoglobulin-like receptors (KIRs) were associated with a reduced risk for relapse, but without any survival advantage.
Major finding: Higher inhibitory KIR (subhazard ratio [SHR], 0.86; P = .01) and missing KIR (SHR, 0.84; P = .02) scores were associated with a reduced risk for relapse. Patients with inhibitory ‘maxima’ (IM)-KIR of 5 had a lower risk for relapse (SHR, 0.80; P = .004) vs those with IM of less than 5. However, increased transplant-related mortality (SHR, 1.32; P less than .05) was observed in 8/8 HLA-matched DRPs with IM 5 vs less than 5.
Study details: Findings are from a retrospective analysis of 2,365 DRPs who underwent unrelated donor HCT with HLA match grade of 8/8 (85%) or 7/8 for early- or intermediate-risk AML.
Disclosures: No specific source of funding was identified for this work. The authors declared no conflicts of interest.
Source: Krieger E et al. Bone Marrow Transplant. 2021 Jul 7. doi: 10.1038/s41409-021-01393-9.
Key clinical point: Among human leukocyte antigen (HLA)-matched donor-recipient pairs (DRPs) who underwent unrelated donor hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), higher inhibitory and missing killer immunoglobulin-like receptors (KIRs) were associated with a reduced risk for relapse, but without any survival advantage.
Major finding: Higher inhibitory KIR (subhazard ratio [SHR], 0.86; P = .01) and missing KIR (SHR, 0.84; P = .02) scores were associated with a reduced risk for relapse. Patients with inhibitory ‘maxima’ (IM)-KIR of 5 had a lower risk for relapse (SHR, 0.80; P = .004) vs those with IM of less than 5. However, increased transplant-related mortality (SHR, 1.32; P less than .05) was observed in 8/8 HLA-matched DRPs with IM 5 vs less than 5.
Study details: Findings are from a retrospective analysis of 2,365 DRPs who underwent unrelated donor HCT with HLA match grade of 8/8 (85%) or 7/8 for early- or intermediate-risk AML.
Disclosures: No specific source of funding was identified for this work. The authors declared no conflicts of interest.
Source: Krieger E et al. Bone Marrow Transplant. 2021 Jul 7. doi: 10.1038/s41409-021-01393-9.